| News
Rhizen drug secures approval in the USA
10.02.2021
The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered this inhibitor for the treatment of cancer.

Swaroop Vakkalanka, President and CEO of Rhizen Pharmaceuticals (img: Rhizen)
Rhizen Pharmaceuticals has discovered Umbralisib, a medication that has now been approved by the US Food and Drug Administration (FDA) for the treatment of patients with certain types of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Rhizen licensed the inhibitor to TG Therapeutics based in the USA, which also did its total clinical development. The Basel biotech has retained commercialization rights for India as well as being the manufacturing and supply partner for Umbralisib, as was reported in a press release.
Umbralisib is an oral, once daily, inhibitor of phosphoinositide 3 kinase delta and casein kinase 1 epsilon. “Umbralisib’s approval offers MZL and FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities,“ said Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals, in the press release.
Rhizen relocated from La Chaux-de-Fonds in the canton of Neuchâtel to Basel in December 2020, with support from Basel Area Business & Innovation, the investment and innovation promotion agency. At the new main location in Basel, the clinical development and commercialization of the novel oncology and inflammation medicines are to be promoted. In particular, Rhizen wants to benefit from the proximity to the Basel Area life sciences cluster. It furthermore plans to grow and create local jobs, so the highly qualified talent offered by Basel was another key factor.
“Basel with its vibrant biotech and pharma ecosystem offers the best opportunity for Rhizen to expand and focus on clinical development of its rich pipeline of investigational drugs,” explained Vakkalanka.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
How Moderna is growing in Switzerland
The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...
Read MoreSandoz decides on Basel for headquarters
Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...
Read MoreVectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read More